You are viewing an expired study
This study is not currently recruiting Study Participants on If you would like to find active studies please search for clinical trials

Homewood, Alabama

  • induced Constipation


The purpose of this study is to evaluate the efficacy and safety of naldemedine in the treatment of opioid-induced constipation (OIC) in subjects with non-malignant chronic pain who are not using laxatives

Study summary:

This is a Phase 3, multi-center, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of naldemedine 0.2 mg once daily versus placebo for the treatment of subjects with non-malignant chronic pain and OIC.


Inclusion Criteria: - Subjects aged 18 to 80 years inclusive at the time of informed consent - Subjects must have non-malignant chronic pain treated with opioids and must have opioid-induced constipation (OIC) - Subjects must be treated with a stable opioid regimen at a total daily dose on average of ≥ 30 mg equivalents of oral morphine sulfate - Subjects must not be currently using laxatives or must be willing to discontinue laxative use at Screening and must be willing to use only the rescue laxatives provided throughout the study duration - Subjects must meet opioid-induced constipation criteria based on the Bowel Movement and Constipation Assessment (BMCA) Diary Exclusion Criteria: - Evidence of significant structural abnormalities of the gastrointestinal (GI) tract - Evidence of active medical diseases affecting bowel transit - History or presence of pelvic disorders that may be a cause of constipation - Surgery (except for minor procedures) within 60 days of Screening - History of chronic constipation prior to starting analgesic medication or any potential non-opioid cause of bowel dysfunction that may be a major contributor to the constipation (e.g., mechanical GI obstruction) - Subjects who have never taken laxatives for the treatment of OIC - History of active treatment for cancer within the last 2 years (except for basal cell or squamous cell carcinoma of the skin that have been successfully resected) or tamoxifen [Nolvadex®] and raloxifene [Evista®] when being used for prevention of breast cancer - Current use of any prohibited medication including opioid antagonists, partial agonists, or mixed agonists/antagonists



Primary Contact:

Study Director
Shionogi Clinical Trials Administrator Clinical Support Help Line

Backup Contact:


Location Contact:

Homewood, Alabama
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: March 26, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.